Results 61 to 70 of about 33,038 (222)
Pharmacotherapeutic strategies for castrate-resistant prostate cancer
Expert Opinion on Pharmacotherapy, 2020 Metastatic castration-resistant prostate cancer (CRPC) is a potentially symptomatic disease with an eventual lethal outcome. Novel pharmaceutical agents are continuously studied with encouraging results in CRPC.In this perspective, the authors present established and promising pharmacotherapeutic strategies for the management of CRPC; both with and ...
Moussa, M. +4 more
openaire +3 more sources
Interdisciplinary Medicine, EarlyView.In the progression of docetaxel resistance, downregulation of FAM107A releases its transcriptional repression of TTK, leading to TTK upregulation. TTK enhances the interaction and phosphorylation of OPTN. This activates mitophagy in tumor cells, facilitates clearance of damaged mitochondria, reduces intracellular reactive oxygen species accumulation ...
Yishan Zhang +11 more
wiley +1 more source
Reappraisal of glucocorticoids in castrate-resistant prostate cancer
Asian Journal of Andrology, 2014 Recent reports and discussions of preclinical prostate cancer models have emphasized the possibility that enzalutamide resistance may be mediated by glucocorticoid receptors (GR). In both in vitroand xenograft animal studies, it is possible to show that the GR is up-regulated in prostate cancer cell lines and that dexamethasone reverses enzalutamide ...
Oliver Sartor +2 more
openaire +3 more sources
Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research
Mass Spectrometry Reviews, EarlyView.Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik +3 more
wiley +1 more source
Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
Frontiers in Oncology, 2019 Most prostate cancers are androgen-sensitive malignancies whose growths depend on the transcriptional activity of the androgen receptor (AR). In the 1940s, Charles Huggins demonstrated that the surgical removal of testes in men can result in a dramatic ...
Qin Feng, Bin He, Bin He
doaj +1 more source
The Journal of Pathology, EarlyView.Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi +8 more
wiley +1 more source
The Prostate, EarlyView.ABSTRACT Background Upfront treatment intensification with androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor has become a standard approach for metastatic hormone‐sensitive prostate cancer (mHSPC). However, prognosis remains poor for some patients despite second‐generation androgen receptor antagonist‐based doublet therapy.
Saizo Fujimoto +14 more
wiley +1 more source
Smart Molecules, EarlyView.The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou +4 more
wiley +1 more source
IJU Case Reports, 2019 Introduction Abiraterone acetate in combination with prednisone is now widely used for the treatment of castration‐resistant prostate cancer. Case presentation A 62‐year‐old patient with a bone metastatic castration‐resistant prostate cancer was started ...
Yoshinori Yanai +3 more
doaj +1 more source
Smart Molecules, EarlyView.AI is transforming TPD by improving the design, prediction, and optimization of degraders such as PROTACs, molecular glues, and LYTACs. This review summarizes key AI‐driven advances, highlights applications across drug discovery stages, and discusses remaining challenges and future directions for accelerating the development of therapies against ...
Shuanglin Qin +10 more
wiley +1 more source